These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 19827834)

  • 1. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
    Aronov AM; Tang Q; Martinez-Botella G; Bemis GW; Cao J; Chen G; Ewing NP; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Markland W; Namchuk MN; Nanthakumar S; Poondru S; Straub J; ter Haar E; Xie X
    J Med Chem; 2009 Oct; 52(20):6362-8. PubMed ID: 19827834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors.
    Aronov AM; Baker C; Bemis GW; Cao J; Chen G; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Martinez-Botella G; Namchuk MN; Straub J; Tang Q; Xie X
    J Med Chem; 2007 Mar; 50(6):1280-7. PubMed ID: 17300186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.
    Wallace MB; Adams ME; Kanouni T; Mol CD; Dougan DR; Feher VA; O'Connell SM; Shi L; Halkowycz P; Dong Q
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4156-8. PubMed ID: 20621728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
    Smith AL; DeMorin FF; Paras NA; Huang Q; Petkus JK; Doherty EM; Nixey T; Kim JL; Whittington DA; Epstein LF; Lee MR; Rose MJ; Babij C; Fernando M; Hess K; Le Q; Beltran P; Carnahan J
    J Med Chem; 2009 Oct; 52(20):6189-92. PubMed ID: 19764794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
    Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.
    Wagner J; von Matt P; Sedrani R; Albert R; Cooke N; Ehrhardt C; Geiser M; Rummel G; Stark W; Strauss A; Cowan-Jacob SW; Beerli C; Weckbecker G; Evenou JP; Zenke G; Cottens S
    J Med Chem; 2009 Oct; 52(20):6193-6. PubMed ID: 19827831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
    Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors.
    Dietrich J; Gokhale V; Wang X; Hurley LH; Flynn GA
    Bioorg Med Chem; 2010 Jan; 18(1):292-304. PubMed ID: 19962319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
    Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
    Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
    Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
    Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
    J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.
    de Vicente J; Lemoine R; Bartlett M; Hermann JC; Hekmat-Nejad M; Henningsen R; Jin S; Kuglstatter A; Li H; Lovey AJ; Menke J; Niu L; Patel V; Petersen A; Setti L; Shao A; Tivitmahaisoon P; Vu MD; Soth M
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4969-75. PubMed ID: 25262541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based virtual screening of Src kinase inhibitors.
    Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
    Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
    Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C
    J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors.
    Buchstaller HP; Burgdorf L; Finsinger D; Stieber F; Sirrenberg C; Amendt C; Grell M; Zenke F; Krier M
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2264-9. PubMed ID: 21420298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using cells devoid of RAS proteins as tools for drug discovery.
    Urosevic J; Sum EY; Moneo V; Drosten M; Dhawahir A; Becerra M; Carnero A; Barbacid M
    Mol Carcinog; 2009 Nov; 48(11):1038-47. PubMed ID: 19526460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.